Why the study?
Despite growing evidence for pharmacogenomics in cardiovascular pharmacology, international cardiovascular societies lack a common position to unite diverse availability, interpretation, application, and clinical practice variations across Europe.
This ESC position statement outlines the challenges and considerations for implementing pharmacogenomic testing in cardiovascular clinical practice across Europe.
Answers are grounded in this paper and cite their sources.
Clinicians should await resolved barriers before routine testing; challenges assumptions of ready implementation in European cardiovascular medicine.
There is a strong and ever-growing body of evidence regarding the use of pharmacogenomics to inform cardiovascular pharmacology. However, there is no common position taken by international cardiovascular societies to unite diverse availability, interpretation, and application of such data, nor is there recognition of the challenges of variation in clinical practice between countries within Europe. Aside from the considerable barriers to implementing pharmacogenomic testing and the complexities of clinically actioning results, there are differences in the availability of resources and expertise internationally within Europe. Diverse legal and ethical approaches to genomic testing and clinical therapeutic application also require serious thought. As direct-to-consumer genomic testing becomes more common, it can be anticipated that data may be brought in by patients themselves, which will require critical assessment by the clinical cardiovascular prescriber. In a modern, pluralistic and multi-ethnic Europe, self-identified race/ethnicity may not be concordant with genetically detected ancestry and thus may not accurately convey polymorphism prevalence. Given the broad relevance of pharmacogenomics to areas, such as thrombosis and coagulation, interventional cardiology, heart failure, arrhythmias, clinical trials, and policy/regulatory activity within cardiovascular medicine, as well as to genomic and pharmacology subspecialists, this position statement attempts to address these issues at a wide-ranging level.
No takes yet. Share an insight, caveat, or question.
Magavern et al. (2021) conducted a review in Cardiovascular disease. Pharmacogenomic testing was evaluated. Pharmacogenomic testing in cardiovascular medicine faces considerable barriers to implementation, including diverse legal, ethical, and resource challenges across Europe.
Synapse has enriched 10 related papers. Consider them for comparative context: